Tuberous Sclerosis Complex-1 Deficiency Attenuates Diet-Induced Hepatic Lipid Accumulation by Kenerson, Heidi L. et al.
Tuberous Sclerosis Complex-1 Deficiency Attenuates
Diet-Induced Hepatic Lipid Accumulation
Heidi L. Kenerson
1, Matthew M. Yeh
2, Raymond S. Yeung
1,2*
1Department of Surgery, University of Washington, Seattle, Washington, United States of America, 2Department of Pathology, University of Washington, Seattle,
Washington, United States of America
Abstract
Non-alcoholic fatty liver disease (NAFLD) is causally linked to type 2 diabetes, insulin resistance and dyslipidemia. In a
normal liver, insulin suppresses gluconeogenesis and promotes lipogenesis. In type 2 diabetes, the liver exhibits selective
insulin resistance by failing to inhibit hepatic glucose production while maintaining triglyceride synthesis. Evidence
suggests that the insulin pathway bifurcates downstream of Akt to regulate these two processes. Specifically, mTORC1 has
been implicated in lipogenesis, but its role on hepatic steatosis has not been examined. Here, we generated mice with
hepatocyte-specific deletion of Tsc1 to study the effects of constitutive mTORC1 activation in the liver. These mice
developed normally but displayed mild hepatomegaly and insulin resistance without obesity. Unexpectedly, the Tsc1-null
livers showed minimal signs of steatosis even under high-fat diet condition. This ‘resistant’ phenotype was reversed by
rapamycin and could be overcome by the expression of Myr-Akt. Moreover, rapamycin failed to reduce hepatic triglyceride
levels in models of steatosis secondary to Pten ablation in hepatocytes or high-fat diet in wild-type mice. These observations
suggest that mTORC1 is neither necessary nor sufficient for steatosis. Instead, Akt and mTORC1 have opposing effects on
hepatic lipid accumulation such that mTORC1 protects against diet-induced steatosis. Specifically, mTORC1 activity induces
a metabolic shift towards fat utilization and glucose production in the liver. These findings provide novel insights into the
role of mTORC1 in hepatic lipid metabolism.
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Introduction
NAFLD represents a spectrum of changes in the liver that are
closely associated with obesity, type II diabetes and other
manifestations of the metabolic syndrome [1][2]. The accumula-
tion of triglycerides (TG) in the liver, known as steatosis, is the
initial and requisite event in the pathogenesis of NAFLD [1]. Over
time, steatosis may progress to steatohepatitis, which is becoming a
major contributor to chronic liver disease including cirrhosis and
primary liver cancers in the United States. Weight reduction
(including bariatric surgery) and exercise are the only widely
accepted treatments for patients with NAFLD. Recent study
suggests that vitamin E and pioglitazone may be beneficial, but
their long-term effects are not known [3].
The widely recognized association between NAFLD and insulin
resistance suggests a role of the insulin signaling pathway in
hepatic steatosis. As a growth factor, insulin activates PI3K
through its interaction with the insulin receptor and its substrate,
IRS1/IRS2 [4]. The catalytic function of PI3K generates second
messengers (e.g., PIP3) to promote PDK1- and mTORC2-
dependent phosphorylation of Akt, while PTEN inhibits this
process by reducing PIP3 through its phosphatase activity [5][6].
Once activated, Akt phosphorylates FoxO1 and inhibits the
transcription of genes required for gluconeogenesis (e.g., phos-
phoenolpyruvate carboxykinase [PEPCK]). Insulin also stimulates
lipid synthesis in the liver via SREBP1c-mediated transcription of
lipogenic genes. In type 2 diabetes, hepatic glucose production
becomes insensitive to insulin while TG production remains
responsive resulting in selective hepatic insulin resistance [7].
Consequently, this leads to the classic triad of hyperinsulinemia,
hyperglycemia and hypertriglyceridemia found in the metabolic
syndrome.
Recent studies highlight the role of mTORC1 in lipogenesis and
provide an understanding for the selective hepatic insulin
resistance in type 2 diabetes [8]. Firstly, it was shown that Akt-
dependent lipogenesis is mediated by mTORC1 through its effects
on SREBP-1c [9]. This is supported by the work of Duvel et al.
showing increased lipogenesis in Tsc22/2 cells, and the work of
others highlighting the effects of rapamycin on the inhibition of
multiple lipogenic enzymes (e.g., FASN, ACC, SCD-1) [10] [11]
[12]. Secondly, mTORC1 participates in adipogenesis by
promoting the translation of C/EBP-a, and PPAR-c, which
further direct the transcription of lipogenic genes [13]. Thirdly,
SREBP1c, but not PEPCK, expression was stimulated by
mTORC1 in the liver suggesting that mTORC1 may be the
bifurcation point for insulin action on lipid and carbohydrate
metabolism [14]. Fourthly, published reports show that events up-
stream (i.e., loss of PTEN [15,16] and LKB1 [17], activation of
Akt [18]) and down-stream (i.e., loss of 4E-BP1/2 [19], activation
of SREBP1 [20]) of mTORC1 can induce steatosis. Finally,
animal models of obesity and type II diabetes such as the Zucker
rat and the ob/ob mouse, as well as diet-induced models of
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[21] [22] [23]. Collectively, the current view suggests that
mTORC1 promotes SREBP1-dependent lipogenesis while it
suppresses Akt-mediated effects on gluconeogenesis; however,
direct evidence causally linking mTORC1 to the pathogenesis of
steatosis remains lacking.
mTOR (mammalian target of rapamycin) is a highly conserved
serine/threonine kinase that plays a central role in the regulation
of cell growth in response to environmental cues: energy, nutrients,
stress, and oxygen [24]. It forms two known multi-protein
complexes: mTORC1 consisting of mTOR, mLST8, Raptor,
Deptor and PRAS40, and mTORC2 containing mTOR, mLST8,
mSin1, Rictor, Deptor and Protor-1. Upon activation by Rheb-
GTPase, mTORC1 enhances protein translation and ribosomal
biogenesis in a rapamycin-sensitive manner. In contrast,
mTORC2 phosphorylates Akt, SGK1, and PKC, and is
insensitive to rapamycin. Studies have identified a central role of
the tuberous sclerosis complex (TSC1/TSC2) in negatively
regulating mTORC1 function by serving as a GTPase activating
protein to suppress the activity of Rheb [25] [26] [27] [28].
Phosphorylation of TSC2 by Akt, ERK and RSK in response to
growth factors results in mTORC1 activation [29]. TSC1
functions to stabilize TSC2 and maintains its proper subcellular
localization [30] [31]. Hence, the loss of either TSC1 or TSC2
gives rise to persistent mTORC1 activity, which initiates a
negative feedback via S6K1 phosphorylation of IRS to suppress
PI3K signaling [32]. In the absence of TSC1 or TSC2, cells
possess high mTORC1 and low Akt activities; this provides a
unique opportunity to examine the function of mTORC1 without
the concomitant influence of Akt.
In this study, we examined the in vivo consequence of mTORC1
activation in the liver by genetically ablating Tsc1 in hepatocytes.
To our surprise, liver-specific Tsc12/2 mice not only failed to
show evidence of steatosis, but also were resistant to triglyceride
accumulation in the liver when challenged with a high-fat diet. We
further demonstrate that mTORC1 is neither sufficient nor
necessary for steatosis, and that Akt and mTORC1 activities have
opposing effects on hepatic accumulation of TG. These findings
provide additional insights into the role of the Akt/mTORC1
pathway in hepatic lipid metabolism.
Methods
Ethics Statement
All animal work was conducted in accordance with national
guidelines and has been approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of
Washington under protocol 3051-03. Euthanasia was performed
using compressed carbon dioxide (CO2) from gas cylinders or
cervical dislocation under anesthesia. We adhered to all policies
and recommendations from the American Veterinary Medical
Association.
Chemicals and antibodies
Rapamycin was obtained from Calbiochem (now EMD,
Gibbstown, NJ). Antibodies for HA tag, Tubulin, and Actin were
purchased from Sigma (St. Louis, MO). Antibodies for Adipophi-
lin and b-galactosidase were purchased from Promega (San Luis
Obispo, CA). The Tsc2 antibody was purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA) and the antibody for Total
GSK-3b was purchased from BD Biosciences (San Jose, CA). All
other antibodies were purchased from Cell Signaling Technology
(Danvers, MA).
Animals
Tsc1
flox/flox mice were obtained from David Kwiatkowski at
Brigham and Women’s Hospital (Boston, MA). Pten
flox/flox
(#006068) and Alb-Cre (#003574) mice were purchased from
Jackson laboratories (Bar Harbor, ME). Tsc1
flox/flox and Pten
flox/flox
mice were bred with Alb-Cre mice to generate progeny with
hepatocyte-specific Tsc1 and Pten deletion respectively. Wild-type
littermates were used as controls. All experiments were done in
accordance with the IACUC at the University of Washington,
Seattle.
For characterization of the Tsc1-null and Pten-null livers, mice
were fasted overnight (less than 12 hours). For acute rapamycin
treatment, mice received an intraperitoneal injection of rapamycin
(2 mg/kg) or vehicle control six hours prior to sacrifice. For
rapamycin-treated Pten2/2 mice, male mice were treated with an
intraperitoneal (IP) injection of 2 mg/kg of rapamycin (diluted in
DMSO) or DMSO vehicle once daily Monday through Friday for
two weeks, starting at 12 weeks of age. For Tsc12/2 mice
challenged on high-fat diet, six-week old, female mice were placed
on either the Surwit high fat diet (HFD) or normal chow diet (NCD)
for six weeks. The rapamycin treated cohort of Tsc12/2 mice on
HFD was administered 2 mg/kg of rapamycin or vehicle control
(M,W,F) starting at week eight for four weeks. Body weights were
monitored weekly and animals were fasted before sacrifice.
Diet-induced Steatosis
Male, wild-type C57BL/6J mice were purchased from Jackson
Laboratories (Bar Harbor, ME). At eight weeks of age mice were
placed on either NCD (PicoLab Rodent Diet 20, 5053) composed
of 25% protein, 13% fat, and 62% carbohydrate, from LabDiet or
the Surwit HFD, (D12330, 16.4% protein, 25.5% carbohydrate,
58% fat) purchased from Research Diets Inc. (New Brunswick,
NJ). Mice were divided into five groups: NCD for six weeks, HFD
for six weeks, HFD for 4 weeks with reversion to NCD for two
weeks, NCD for six weeks with rapamycin treatment for last two
weeks, and HFD for six weeks with rapamycin treatment for the
last two weeks. Mice were treated with 2 mg/kg of rapamycin (M,
W, F) for two weeks.
Adenovirus Injection
Tsc12/2 mice were injected with 1610
7 plaque-forming units
per gram of body weight of either Myr-HA-Akt1 or b-gal control
adenovirus (Vector Biolabs, Philadelphia, PA) in 200 ml of saline
via tail vein injection. Four days after injection fasted mice were
sacrificed and tissues procured for analysis.
Glucose Tolerance Test and Insulin Sensitivity Tests
For Glucose Tolerance Test (GTT), mice were fasted for sixteen
hours and weighed. After sixteen hours, fasting blood glucose was
obtained from venous blood via tail nick and measured with
OneTouch blood glucose monitoring system and test strips from
LifeScan, Inc. (Milpitas, CA). Mice received an IP injection of
glucose (1 mg/g body weight). Blood glucose values were obtained
at 15, 30, 60, and 120 minutes. At 30 minutes 50 ml of blood was
procured for insulin assay. For the Insulin Sensitivity Tests (IST)
mice were fasted for four hours and weighed. After fasting, a blood
glucose level was obtained at time 0 and then 0.5 mU/g of insulin
was given via IP injection and additional blood glucose values were
obtained at 15, 30, 60, and 120 minutes.
Systemic and hepatic insulin response
Tsc12/2 and Tsc1+/+ mice were fasted for eight hours before
insulin injection. Thirty minutes prior to insulin injection mice
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0.5 mU/g of insulin (Lilly, Indianapolis, Indiana) in 500 mlo f
saline or just 500 ml of saline alone via IP injection. Ten minutes
after injection, mice were euthanized via cervical dislocation.
Tissues were procured immediately upon sacrifice and processed
for protein analysis.
Western Blot
Mouse liver, white adipose tissue (WAT), and muscle were
homogenized in ice-cold radioummunoprecipitation (RIPA) buffer
(1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 0.15 M
NaCl, 10 mM Tris (pH 7.2), 0.025 M b-glycophosphate (pH 7.2),
2 mM EDTA, and 50 mM sodium fluoride) with protease and
kinase inhibitors (0.05 mM AEBSF, 10 mg/ml aprotinin, 10 mg/
ml pepstatin, 1 mM orthovanadate, 10 mg/ml leupeptin, 1 mM
microcystin LR). The protein concentration was measured using
the BCA Protein Assay (Pierce, Rockford, IL). Equal amounts of
protein were separated by SDS-PAGE, transferred to Immobilin-P
membranes (Millipore, Bedford, MA) and blotted with antibodies
according to manufacturer recommendations.
Histology
Slides were deparaffinized, rehydrated, and washed before
staining with hematoxylin QS and eosin (Vector Laboratories,
Burlingame, CA) and mounting with Permount (Fischer Scientific,
Santa Clara, CA). For Oil Red O staining, 5 micron thick frozen
sections were cut and stained with Oil Red O diluted in propylene
glycol.
Plasma Metabolic Parameters
Blood was extracted via cardiac puncture immediately after
sacrifice. Blood was spun for 15 minutes at 3000 rpm at 4uC.
Plasma was analyzed for glucose, triglycerides, leptin, adiponectin,
and insulin. Plasma insulin, leptin, adiponectin were quantified
using Luminex and Linco Elisa Kits (Millipore, Billerica, MA).
Plasma triglycerides were quantified via a colorimetric assay using
a triglyceride assay kit from Roche Diagnostics.
Liver Triglyceride Analysis
Lipids were extracted from 100 mg of liver tissue using
chloroform:methanol and solubilized in 1% triton X-100/
chloroform (v/v) [33]. Liver triglycerides were quantified via a
colorimetric assay using a triglyceride assay kit from Roche
Diagnostics.
Real-time PCR
Total RNA was extracted from fresh/frozen liver tissue using
TRIzol (Invitrogen, Carlsbad, CA) according to the manufacture’s
instructions. Three micrograms of RNA was reverse transcribed
using Promega M-MLV Reverse Transciptase. PCR for sterol
regulatory element binding protein 1c (SREBP1c) (PrimerBank ID
14161491a1), adipose triglyceride lipase (ATGL), fatty acid
synthase (FASN) (PrimerBank ID 309119099a1), glucokinase
(GK) (PrimerBank ID 31982798a1), phosphoenolpyruvate car-
boxykinase1 (PEPCK) (PrimerBank ID 7110683a1), peroxisome
proliferator activated receptor gamma (PPARg) (PrimerBank ID
6755138a1), PPAR gamma co-activator (PGC1) alpha (Primer-
Bank ID 6679433a1), apolipoprotein B (ApoB) (PrimerBank ID
930134a1), microsomal triglyceride transfer protein (Mttp) (Pri-
merBank ID 6678960a1) ribosomal protein L32 (L32 sybr)
(PrimerBank ID 25742730a1) genes were performed using the
primer sequences listed in Table 1.
Statistical analyses
Quantitative data were analyzed by unpaired t-test. A p-value of
less than 0.05 was considered significant.
Results
A. Liver-specific ablation of Tsc1 leads to hepatomegaly
and insulin resistance
To investigate the biologic effects of mTORC1 in the liver, we
ablated a key negative regulator of mTORC1, Tsc1,i n
hepatocytes by crossing Albumin-Cre mice with animals carrying
floxed alleles of Tsc1. The resulting Tsc1
flox/flox;Alb-Cre mice (a.k.a.
Tsc12/2) showed liver-specific loss of Tsc1 that was accompanied
by a reduction in steady-state Tsc2 expression secondary to the
known influence of Tsc1 on Tsc2 stability [30] (Figure 1A).
Consequently, the Tsc12/2 livers possessed constitutively active
mTORC1 as shown by increased expression of phospho-
S6K1(Thr389) and phospho-S6(Ser235/236), and this activity
was inhibited by rapamycin (Figure 1B).
The Tsc12/2 mice developed normally and were fertile. At 20
weeks of age, average total body weight of the mutant mice was
not statistically different from the wild-type mice (29.7 g vs. 27.2 g,
Table 1. Primer sequences used in qRT-PCR.
Gene Name Forward Reverse
ACLY 59-CAGCCAAGGCAATTTCAGAGC-39 59- CTCGACGTTTGATTAACTGGTCT-39
ATGL 59- TGTGGCCTCATTCCTCCTAC-39 59- TGCTGGATGTTGGTGGAGCT-39
FASN 59- GGAGGTGGTGATAGCCGGTAT-39 59- TGGGTAATCCATAGAGCCCAG-39
GK 59- TGAGCCGGATGCAGAAGGA-39 59- GCAACATCTTTACACTGGCCT-39
PEPCK 59- CTGCATAACGGTCTGGACTTC-39 59- CAGCAACTGCCCGTACTCC-39
PPARg 59- TCGCTGATGCACTGCCTATG-39 59- GAGAGGTCCACAGAGCTGATT-39
SREBP1c 59- GCAGCCACCATCTAGCCTG-39 59- CAGCAGTGAGTCTGCCTTGAT-39
PGC1alpha 59-TATGGAGTGACATAGAGTGTGCT-39 59-TATGGAGTGACATAGAGTGTGCT-39
ApoB 59-TTGGCAAACTGCATAGCATCC-39 59-TCAAATTGGGACTCTCCTTTAGC-39
Mttp 59-CTCTTGGCAGTGCTTTTTCTCT-39 59-GAGCTTGTATAGCCGCTCATT-39
L32 SYBR 59- TTAAGCGAAACTGGCGGAAAC-39 59- TTGTTGCTCCCATAACCGATG-39
doi:10.1371/journal.pone.0018075.t001
mTORC1 Protects against Steatosis
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e18075p=0.13), while their absolute liver weights (1.17 g vs. 0.91 g,
p=0.002) and liver:body weight ratios (3.9% vs. 3.4%, p=0.002)
were significantly higher compared to wild-type littermates
consistent with hepatomegaly. The weights of the white adipose
tissue (WAT) were comparable between the two groups (0.87 g vs.
0.75 g, p=0.63). To determine systemic insulin response in these
animals, glucose tolerance tests and insulin sensitivity tests were
performed. Following systemic administration of glucose, both
male and female Tsc12/2 mice exhibited mild but significant
glucose intolerance compared to Tsc1+/+ mice (Figure 1C). This
was accompanied by a slight reduction in systemic insulin
sensitivity (Figure 1C). Fasting plasma glucose and insulin levels
were not significantly different between the Tsc1+/+ and Tsc12/2
mice, while the insulin levels at 30 minutes following glucose
administration were higher in the mutant mice (Figure 1D). These
observations suggest that the hepatic-specific Tsc12/2 mice are
insulin resistant.
To further examine the response to insulin in the liver, WAT
and muscle tissues, fasted mice were given 0.5 U/kg of insulin 10
minutes before sacrifice. As expected, insulin led to a significant
Figure 1. Hepatocyte-specific deletion of Tsc1 leads to mild insulin resistance. A. Liver-specific ablation of Tsc1. Tsc1
fl/fl mice were crossed
to Cre
Alb mice resulting in Tsc1
fl/fl; Cre
+/+ (a.k.a. Tsc1+/+) and Tsc1
fl/fl; Cre
Alb (a.k.a. Tsc12/2) littermates. Tissues from eight-week old Tsc12/2 and
Tsc1+/+ animals were analyzed for the expression of Tsc1, Tsc2 and S6K by immunoblot analyses using the indicated antibodies. WAT, white adipose
tissues. Note the reduced Tsc2 expression secondary to its diminished stability in the absence of Tsc1 [30]. B. The loss of Tsc1 in hepatocytes resulted
in increased mTORC1 activity (based on the expression of phospho-S6K and phospho-S6) that was sensitive to rapamycin. Tsc12/2 mice were fasted
and treated with or without rapamycin (2 mg/kg IP, 6 hrs). Liver lysates were analyzed by SDS-PAGE and blotted with the indicated antibodies. Note
the effect of rapamycin on Akt phosphorylation in the Tsc12/2 liver. Actin, loading control. C. Systemic glucose tolerance (left) and insulin sensitivity
(right) tests in 8-week old female (top) and male (bottom) mice. Following a 16-hr fast, glucose (1 mg/g) was given IP followed by serial blood
glucose monitoring at indicated times. For insulin sensitivity test, 0.5 mU/g of insulin was injected IP after a 4-hr fast. *, p,0.05 between the Tsc1+/+
and Tsc12/2 groups. D. Fasting blood glucose and insulin levels in wild-type and mutant mice. Plasma insulin levels 30 minutes after glucose
administration are also shown (filled boxes).
doi:10.1371/journal.pone.0018075.g001
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animals (Figure 2A,B). However, the Akt response to insulin was
dramatically blunted in the tissues derived from the Tsc12/2
mice. In the case of the Tsc12/2 hepatocytes, hyperactivity of
mTORC1 is known to inhibit Akt secondary to feedback
inhibition on IRS1 [32]. Consequently, both baseline and
insulin-stimulated Akt activities were suppressed in the Tsc12/2
liver (Figure 2A). In contrast, basal Akt phosphorylation in WAT
and muscle tissues were elevated in the mutant mice relative to
wild-type controls while insulin-stimulated response was signifi-
cantly reduced (Figure 2B). This finding cannot be explained by
the ‘feedback’ mechanism but we speculate that the chronic
systemic exposure to post-prandial hyper-insulinemia (or other
insulin-like growth factors) in the mutant animals may be
responsible. Figure 3C highlights the relative changes in
Akt(Ser473) phosphorylation between the saline- and insulin-
treated wild-type and mutant animals. These results indicate that
the loss of hepatic Tsc1 leads to hepatic and systemic insulin
resistance.
C. Persistent mTORC1 activity is not sufficient for
steatosis
Despite an increase in liver mass and the presence of insulin
resistance, the Tsc12/2 mice showed no histologic or biochem-
ical evidence of excessive TG accumulation in the liver compared
with wild-type littermates (Figure 3A,B). Oil Red ‘‘O’’ staining and
direct TG measurements suggested a trend towards reduced lipids
in the Tsc12/2 livers. Hence, the hepatomegaly in the mutant
mice was not secondary to steatosis but instead, due to a significant
increase in hepatocyte cell size (Figure 3C). This is consistent with
the role of mTORC1 in regulating cell growth [25]. Plasma TG
levels in the Tsc12/2 mice were significantly lower than the wild-
type littermates (55 vs. 88 mg/dl, p,0.05) while adiponectin (+/+:
4,983 pg/ml; 2/2: 5,870 pg/ml, p=0.27) and leptin (+/+:
3,814 pg/ml; 2/2: 3,236 pg/ml, p=0.66) levels were similar
between the two groups. At fasting, mRNA expression of SREBP-
1c involved in lipogenesis was slightly lowered while genes
involved in lipolysis (ATGL) and gluconeogenesis (PEPCK) were
significantly elevated in the Tsc12/2 mice compared to wild-type
animals (Figure 3D). These findings show that hyperactive
mTORC1 in hepatocytes is not sufficient to induce steatosis in
vivo despite evidence of hepatic and systemic insulin resistance.
D. Inhibition of mTORC1 fails to reverse diet-induced
steatosis
Next, we set out to determine if mTORC1 activity is necessary
for steatosis by examining the effects of rapamycin, an mTORC1
inhibitor, on diet-induced steatosis. Six-week old, wild-type male
mice were randomly assigned to receive NCD or HFD (Surwit) for
6 weeks. Within each diet group, animals were further randomized
to receive rapamycin (2 mg/kg) or DMSO (vehicle) given 3 times a
week (e.g., Monday, Wednesday, Friday) via intraperitoneal
injections during the last two weeks of the study. To ascertain
that a two-week duration was sufficient time for a steatotic liver to
recover to baseline, an additional cohort of animals was placed on
HFD for 4 weeks followed by NCD for 2 weeks. Figure 4 shows
Figure 2. Liver, fat and muscle of Tsc12/2 mice show blunted response to insulin. Following an eight-hour fast, mice were injected with
0.5 U/kg of insulin or saline (control) for 10 minutes before sacrifice. A) Liver and B) white adipose tissue (WAT) and skeletal muscle tissue lysates were
analyzed for the expression of indicated proteins. C. Akt response to insulin. The relative band intensities of p-Akt(Ser473) were normalized to total
Akt from (A) and (B), and then the ratios between the insulin- and saline-treated animals were calculated from individual tissues tested.
doi:10.1371/journal.pone.0018075.g002
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compared to those on NCD as expected, but this increase was
quickly lost when HFD fed mice resumed NCD. (i.e., HFD-NCD
group). Rapamycin also dampened the weight gain in mice. The
absolute liver weights were not significantly different among any
group although the ones from the HFD-NCD-fed mice weighed
the least.
HFD was associated with a significant increase in plasma levels
of glucose and insulin suggestive of systemic insulin resistance, and
these parameters returned to baseline within 2 weeks of resuming
normal chow (Figure 4). Rapamycin treatment led to higher
fasting plasma glucose and insulin levels that were most
pronounced in animals receiving HFD. These findings are
consistent with previous reports of glucose intolerance following
chronic rapamycin treatment [34] [35].
Analysis of the livers revealed a significant increase in
triglyceride levels in mice receiving HFD, and importantly,
rapamycin did not alter hepatic TG levels significantly in either
group of animals (Figure 4). This corroborates with the histologic
findings of steatosis in the HFD-groups regardless of rapamycin
treatment (Figure 5A). Further, rapamycin did not lead to any
histologic change in the NCD-fed livers. Immunoblot analyses of
the liver lysates showed a trend towards higher levels of
Akt(Ser473) phosphorylation with HFD that were unchanged
following two weeks of rapamycin (Figure 5B). Hence, despite
evidence of worsening glucose intolerance, mTORC1 inhibition
by rapamycin did not alter hepatic lipid content in a model of diet-
induced steatosis. In contrast, the HFD-associated TG accumu-
lation and insulin resistance reverted to baseline within 2 weeks of
replacing the HFD with NCD. We conclude that mTORC1 is not
necessary for the maintenance of HFD-induced steatosis.
E. Effects of rapamycin on steatosis in liver-specific
Pten2/2 mice
Given that the pathogenesis of HFD-induced steatosis may
involve multiple pathways, the lack of significant change in TG
accumulation following rapamycin treatment could potentially be
explained by other mechanisms that affect lipid metabolism
besides mTORC1. In order to focus on the relevance of
mTORC1 in steatosis, we turned to an established genetic model
of steatosis through Pten ablation in hepatocytes. We generated a
cohort of Pten
flox/flox;Alb-Cre (a.k.a. Pten2/2) mice that showed
Figure 3. mTORC1 activity is not sufficient for steatosis. Normal chow-fed, 20-week old male Tsc1+/+ and Tsc12/2 male mice were fasted
overnight and sacrificed. Liver tissues were processed for histologic and biochemical analyses. A) Liver histology (H&E) and Oil Red ‘‘O’’ staining
showing hepatic morphology and lipid content. Magnification 400X. B) Quantification of liver triglyceride content using TG assay kit (Roche
Diagnostics, see Methods). C) Hepatocyte cell size was deduced based on the average number of hepatocytes per high-power field from 10 randomly
selected fields. *, p,0.01 compared to Tsc1+/+. D) Expression of genes involved in lipogenesis (SREBP1), adipogenesis (PPARg), lipolysis (ATGL) and
gluconeogenesis (PEPCK) were determined by quantitative RT-PCR. *, p,0.05 compared to Tsc1+/+. For all graphs, values represent mean 6SEM.
doi:10.1371/journal.pone.0018075.g003
mTORC1 Protects against Steatosis
PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e18075constitutive Akt activation in the liver (Figure 6A). At 12 weeks of
age, the mutant pups had similar body weights compared to wild-
type littermates but had enlarged, whitish livers containing large
fat vacuoles and elevated TG levels consistent with earlier reports
[15,16]. Compared to the Tsc12/2 mice, the absolute liver
weight and the liver:body ratio were higher in the Pten2/2 mice
while total body weight was similar in the two groups (data not
shown).
Using this model, we tested whether mTORC1 activity was
necessary for steatosis by treating 12-week old animals with
rapamycin (2 mg/kg IP daily, M-F) or vehicle for 2 weeks.
Figure 6A shows that at the end of the treatment period,
rapamycin completely inhibited mTORC1 activity (as indicated
by loss of phospho-S6(Ser235) expression) without significant effect
on Akt activity. Histologic analysis revealed that livers of
rapamycin-treated Pten2/2 mice exhibited a similar degree of
steatosis compared to vehicle-treated animals based on H&E and
Oil Red ‘‘O’’ staining (Figure 6B). However, rapamycin reduced
the average cell size of hepatocytes compared to the vehicle-
treated group as quantified by the number of cells per high-power
field (data not shown). This was also reflected in a reduction in
liver:body weight following rapamycin treatment although it
remained elevated compared to wild-type littermates (data not
shown). Importantly, triglyceride content in the rapamycin-treated
Pten2/2 livers remained unchanged compared to the group
treated with vehicle control, but both Pten2/2 groups had
significantly greater hepatic triglyceride concentration than the
wild-type littermates (Figure 6C). Given that steatosis is rapidly
reversible (e.g., see HFD-NCD in Fig. 4), these findings suggest
that rapamycin affects hepatocyte cell size but not its lipid content.
This led us to conclude that the inhibition of mTORC1 did not
alleviate steatosis in a model where Akt is constitutively active in
the hepatocytes. Further, our results indicate that Akt-induced
lipogenesis is not dependant on mTORC1 activity. Together with
the results of the Tsc1-mutant model and the effects of rapamycin
in the HFD model, we deduce that mTORC1 is neither necessary
nor sufficient for hepatic steatosis.
F. The role of feedback inhibition on Akt
The striking differences in hepatocyte TG content of the two
rodent models (i.e., Tsc1- and the Pten-hepatocyte-specific deletion)
were closely paralleled by the observed disparities in their Akt
activities. Figure 7A highlights the dramatic difference in Akt
signaling in the livers from these two models. While Akt was
markedly activated in the Pten-null livers, its activity was
suppressed in the Tsc1-null state due to the negative feedback of
mTORC1/S6K1 on IRS1 [32]. In both models, hepatocytic
mTORC1 activity was up-regulated compared to wild-type
littermates based on 4E-BP1 mobility shifts, although the Tsc1-
null hepatocytes had significantly higher levels of mTORC1
activity compared to the Pten-null cells (Figure 7A). These
observations led us to postulate that the relative lack of steatosis
Figure 4. Metabolic response to rapamycin following HFD. Six-week old, wild-type mice were randomly assigned to one of 5 groups with
n=5 in each group (see text). At the end of 6 weeks, mice were fasted overnight and sacrificed. Shown are the results of body and liver weights,
fasting serum glucose and insulin, plasma and hepatic triglyceride levels for each group. Values represent mean 6SEM. * associated with HFD
indicates p,0.05 with respect to NCD group. * associated with HFD-rapamycin group indicates p,0.05 with respect to NCD-rapamycin group. NCD,
normal chow diet; HFD, high-fat diet; Rapa, rapamycin.
doi:10.1371/journal.pone.0018075.g004
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suppression of Akt. To test this hypothesis, we introduced a
recombinant adenovirus encoding a constitutively active myris-
toylated form of Akt into the tail vein of the Tsc12/2 mice. Four
days following injection, the Myr-Akt treated livers became
significantly larger (i.e., hepatomegaly) compared to those injected
with control adenovirus encoding b–galactosidase, as previously
reported [18]. Microscopically, the Myr-Akt hepatocytes showed
fat vacuolation consistent with steatosis and biochemically, this
was associated with an up-regulation of adipophilin, a lipid droplet
coat protein (Figure 7B,C). These findings were accompanied by a
marked increase in Akt(Ser473) and GSK3b (Ser9) phosphoryla-
tion in the livers of the Myr-Akt treated Tsc12/2 animals
(Figure 7C). Hence, the up-regulation of Akt in these animals was
sufficient to induce steatosis. These findings also confirm that the
Tsc1-null hepatocytes are capable of fat accumulation in an Akt-
responsive manner. Together, the data suggest that the lack of
steatosis in the Tsc12/2 mice may be secondary to the relative
suppression of Akt activity.
G. Tsc12/2 hepatocytes are resistant to steatosis
induced by HFD
The correlation between hepatic Akt activity and steatosis led us
to predict that mTORC1-mediated suppression of Akt may
protect the Tsc12/2 liver from TG accumulation. To test this
hypothesis, 6-week old Tsc12/2 and Tsc1+/+ littermates were
placed on a high-fat diet or normal chow diet for 6 weeks. Those
assigned to the HFD were further randomized to receive
rapamycin (2 mg/kg IP, MWF) or vehicle control (DMSO) during
the last 4 weeks of the experiment. Over this period, weight gains
on the HFD were marginally less in the mutant animals compared
to wild-type littermates (p.0.10), and the liver:body weight ratio
Figure 5. Histologic and biochemical effects of rapamycin on HFD-induced steatosis. A) Examples of histology (H&E) and Oil Red ‘‘O’’
staining of the livers procured from animals described in Figure 4. NCD, normal chow diet; HFD, high-fat diet; Rapa, rapamycin. Magnification, 400X.
B) Western blots of representative liver lysates from each of the four groups shown in (A) highlighting the effects of chronic rapamycin on Akt(Ser473)
phosphorylation. The average ratios of band intensities (Image J) between phospho- and total-Akt are summarized in the graph (n of 5 per group).
doi:10.1371/journal.pone.0018075.g005
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diet condition (data not shown). In response to HFD, fasting
plasma glucose and insulin levels rose, and rapamycin treatment
further increased the values (Figure 8B). These trends suggest that
glucose intolerance worsened with HFD + rapamycin in both
Tsc1+/+ and Tsc12/2 mice without significant differences
between the two genotypes. Plasma TG increased with HFD in
the wild-type, but not mutant animals, whereas rapamycin
significantly elevated plasma TG levels in the mutant but not
wild-type mice (Figure 8B). On histologic analysis, the livers from
the wild-type and mutant mice in the NCD group were
indistinguishable, but under HFD condition, the Tsc1+/+ mice
developed significant steatosis while the Tsc12/2 livers showed
minimal change based on H&E and Oil Red ‘‘O’’ staining
(Figure 8A). Direct measurements of liver TG revealed significant
increase in lipid accumulation following HFD in the wild-type
animals but not in the Tsc12/2 mice (Figure 8B). We confirmed
these findings using an independent cohort of animals under the
same scheme. After 6 weeks, the results of the hepatic TG levels
were nearly identical with the exception that the Tsc12/2 mice
fed HFD had significantly lower hepatic TG levels than those fed
NCD (6.5 vs. 8.3 mg/g, p,0.01). Together, the histologic and
biochemical evidence suggest that the loss of Tsc1 protects the liver
from TG accumulation.
To determine if the resistance to steatosis in the Tsc12/2 mice
stems from mTORC1 hyperactivity, we treated a cohort of mice
on HFD with rapamycin. The lipid content following rapamycin
rose significantly in the mutant livers along with histologic
evidence of steatosis (Figure 8A, B). Importantly, the levels of
hepatic TG in the Tsc12/2 mice became equivalent to that of the
Tsc1+/+ littermates. These rapamycin-induced phenotypic chang-
es correlated closely with the de-repression of Akt activity (i.e.,
increased phospho-Akt(Ser473) expression) and the inhibition of
mTORC1 activity (i.e., decreased phospho-S6(Ser235/236) ex-
pression) (Figure 8C). As noted earlier, HFD increased basal Akt
phosphorylation in both wild-type and mutant livers although
Figure 6. Effects of rapamycin on Pten2/2 livers. Hepatocyte-specific deletion of Pten was generated by crossing Pten
fl/fl with Cre
Alb mice. At 12
weeks of age, Pten2/2 mice were randomly assigned to treatments with rapamycin (2 mg/kg IP daily, M-F) or DMSO as vehicle control (C) for 2
weeks and then sacrificed. A) Representative Western blot showing the effects of Pten loss (2/2) and rapamycin (Rapa) in the liver with respect to Akt
and mTORC1 signaling. Liver lysates were subjected to immunoblot analyses with the indicated antibodies. B) Liver histology (H&E) and Oil Red ‘‘O’’
staining of Pten+/+ and Pten2/2 mice treated with rapamycin or vehicle control. C) Quantification of liver triglyceride content of the corresponding
groups. Values represent mean 6SEM. *, p,0.05 compared to Pten+/+ group.
doi:10.1371/journal.pone.0018075.g006
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in the absence of significant mTORC1 activity (i.e., +/+ HFD, +/+
HFD-rapa, 2/2 HFD-rapa) was accompanied by steatosis, but
when balanced by high mTORC1 activity (i.e., 2/2 HFD), no
significant lipid accumulated (Figure 8C). These observations are
consistent with our hypothesis that mTORC1 activity protects
against TG accumulation in this dietary model, and that the
development of steatosis is dependent on the balance between
hepatic Akt and mTORC1 activities.
H. Loss of Tsc1 promotes fat utilization and glucose
production
To explore the mechanism for the steatosis-resistant phenotype
in the Tsc12/2 liver, we analyzed the hepatic expression of genes
involved in lipid and glucose metabolism by RT-PCR analyses.
Figures 9A and 9B show the results from the experiments
described in Figure 8 highlighting the effects of Tsc1, HFD and
rapamycin on hepatic metabolic gene expression relative to NCD-
fed wild-type livers. In the Tsc1+/+ mice, HFD induced SREBP1c
and glucose kinase (GK) expression and suppressed ATGL and
PEPCK expression indicative of a metabolic shift towards fat
synthesis and glucose utilization leading to steatosis. The loss of
Tsc1 resulted in an opposite response to HFD with a significantly
blunted increase in SREBP1c and GK expression and an
exaggerated up-regulation of ATGL and PEPCK (Figure 9A).
Further, these changes in the Tsc12/2 livers were reversed with
rapamycin treatment such that the effects of mTORC1 inhibition
resembled the response of the normal liver to HFD. These
observations suggest that the protection from HFD-induced
steatosis in the Tsc12/2 liver stems from a mTORC1-dependent
switch in hepatic metabolism from fat synthesis to fat utilization
and from glucose utilization to glucose production. Moreover,
hepatic PGC1a expression was also rapamycin-sensitive and was
significantly elevated in the Tsc12/2 livers suggestive of an
increase in mitochondrial oxidation. While other factors such as
TG export may influence hepatic lipid accumulation, we did not
find a significant difference in the expression of hepatic
microsomal triglyceride transfer protein (Mttp) between the groups
although ApoB expression in the wild-type livers was significantly
reduced when challenged with the HFD, a response not seen in
the Tsc12/2 mice (Figure 9B).
In contrast, the Pten2/2 mice have high basal SREBP1 and
PPAR-c (data not shown) expression but slightly reduced ATGL
expression in the liver (Figure 9C). Treatment with rapamycin did
not suppress SREBP1, ACLY or FASN expression but rather
increased their levels slightly in the Pten-deficient livers while
ATGL expression remained unchanged (Figure 9C). A remarkably
similar trend in the expression of these lipogenic and lipolytic
enzymes was found in HFD-induced steatosis in wild type mice
suggesting that the effects of HFD closely parallel that of Akt
activation (Figure 9D). Collectively, these data indicate that Akt,
and not mTORC1, positively regulates a SREBP1-dependent
pathway in hepatocytes in vivo.
Figure 7. Akt induces steatosis in the Tsc12/2 livers. A) Contrasting effects of Pten- and Tsc1-loss on Akt signaling in the liver. Immunoblot
analyses of liver lysates from fasted 20 wk-old mice using indicated antibodies to highlight Akt and mTORC1 signaling. B) Effects of Akt on Tsc12/2
livers. Tsc12/2 mice were injected through the tail-vein with adenovirus (10
7 PFUs) encoding genes for Myr-Akt1 or b–galactosidase control. After
96 hours, mice were fasted overnight and sacrificed for H&E histology and Oil Red ‘‘O’’ staining of the livers. Magnification, 400X. C) Expression of
transgenes (HA-tagged Myr-Akt1 or b–gal) and components of the Akt/mTORC1 pathway in the Tsc12/2 livers following adenovirus injections. C,
control for Tsc1 expression. Note up-regulation of Akt without significant alteration to mTORC1 signaling in the Myr-Akt1-treated liver.
doi:10.1371/journal.pone.0018075.g007
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littermates were randomly assigned to normal chow diet (NCD), high fat diet (HFD) or HFD with rapamycin (2 mg/kg IP, 3 times weekly during the last
4 weeks). At the end of 6 weeks on the assigned diets, mice were sacrifice following an overnight fast. A) H&E histology and Oil Red ‘‘O’’ (ORO)
staining of representative liver sections from each of the 6 groups. Magnification 400X. B) Biochemical measurements of liver and plasma triglyceride
(TG), plasma insulin and glucose levels are shown for each of the groups. Values represent mean 6SEM. * p,0.05. C) Western blot analyses of
representative liver lysates from each group showing the effects on Akt/mTORC1 signaling. Blots from long exposure (LE) and short exposure (SE) are
shown for p-Akt(Ser473). Actin, loading control.
doi:10.1371/journal.pone.0018075.g008
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Pten-mutant livers led us to explore its up-stream regulators
including PPARc and FoxO1 that have been shown to control
ATGL expression. Kim et al. reported that PPARc directly
promotes ATGL transcription, and the PPARc agonist, rosiglita-
zone, leads to an increase in ATGL mRNA levels [36]. However,
Figure 9. Hepatic mRNA expression of metabolic genes. Relative expression of genes involved in hepatic lipogenesis (SREBP1, ACLY, FASN),
lipolysis (ATGL), gluconeogenesis (PEPCK), glycolysis (GK), mitochondrial respiration (PGC1a) and triglyceride secretion (ApoB, Mttp) were determined
by RT-PCR analyses of RNA extracted from liver samples derived from experiments described in Figures 4, 6 and 8. All values represent mean 6SEM.
A, B) Comparison of Tsc1+/+ and Tsc12/2 mice fed normal chow (NCD) and high-fat diet (HFD) with and without rapamycin (rapa). * p,0.05 (not all
significant differences are highlighted). C) Pten2/2 mice treated with rapamycin or vehicle (dmso) compared to wild-type littermates, * p,0.05
compared to Pten+/+. D) Gene expression in livers of wild-type mice fed NCD or HFD with or without rapamycin treatment. *p,0.05 compared to
NCD, E) Reduced FoxO1 phosphorylation in Tsc12/2 livers. Tissue lysates from Tsc1+/+ and Tsc12/2 livers were analyzed for the expression of the
indicated proteins by immunoblot analyses. Levels of FoxO1(Ser256) phosphorylation were quantified relative to total FoxO1 expression based on
densitometric analyses (Image J).
doi:10.1371/journal.pone.0018075.g009
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Tsc12/2 HFD-fed livers since high-fat diet suppressed PPARc
expression in both wild-type and mutant mice (data not shown).
On the other hand, the transcription factor, FoxO1, was found to
modulate lipolysis through its regulation of ATGL expression [37].
FoxO1 is an Akt target and upon phosphorylation by Akt, FoxO1
becomes sequestered in the cytoplasm as an inactive protein [38].
We examined the phosphorylation of FoxO1 at Ser256, an Akt
site, using a phospho-specific antibody. Figure 9E shows that
hepatic p-FoxO1(Ser256) expression was significantly reduced
relative to total FoxO1 levels indicating elevated FoxO1 activity in
the Tsc12/2 livers. These findings are consistent with the model
of mTORC1-induced steatosis-resistance secondary to Akt
inhibition and FoxO1 activation.
Discussion
The notion that mTORC1 promotes lipogenesis and may
contribute to NAFLD came from a series of observations showing
the positive effects of mTORC1 on SREBP1 expression and
activity that lead to de novo lipid synthesis [8] [9] [10] [11][14] [39].
In response to insulin in the liver, Li et al. showed that mTORC1
is required for lipogenesis but is not involved in the inhibition of
gluconeogenesis [14]. These and other evidence provide an
understanding for the phenomenon of selective hepatic insulin
resistance observed in type 2 diabetes [7]. In this study, we directly
examined the effects of mTORC1 hyperactivity in genetically
engineered mice with hepatocyte-specific deletion of Tsc1,a
negative regulator of mTORC1. While the normal-chow diet-fed
Tsc12/2 animals displayed evidence of hepatic and systemic
insulin resistance, their livers did not show signs of steatosis, and
the corresponding levels of hepatic triglyceride and expression of
lipogenic genes (e.g., SREBP1, ACLY, FASN) were similar to
those of the wild-type littermates. These findings suggest that
constitutive mTORC1 activation per se is not sufficient for the
development of steatosis. We further tested the effects of
rapamycin in two independent models of steatosis to determine
if mTORC1 activity is necessary for triglyceride accumulation in
hepatocytes. Six weeks of high-fat (Surwit) diet in the wild-type
mice gave rise to hypertriglyceridemia, hyperglycemia, hyperin-
sulinemia and steatosis that are commonly associated with the
metabolic syndrome. Pten deletion in hepatocytes results in
profound hepatomegaly and steatosis as previously reported [15]
[16]. In both models, hepatic Akt2 has been shown to be the key
mediator of lipid accumulation [40] [41]. Two weeks of rapamycin
treatment significantly reduced mTORC1 activity but failed to
suppress hepatic triglyceride levels in either model. Instead, there
was a trend towards higher expression of lipogenic genes (e.g.,
SREBP1c) following rapamycin treatment. These observations led
us to conclude that mTORC1 is neither necessary nor sufficient
for steatosis.
mTORC1 is a key effector downstream of Akt involved in cell
growth and proliferation [24]. Activation of either Akt or
mTORC1 can lead to tumor formation [42] [43]. However, in
the liver, these two kinases appear to have opposing effects on lipid
accumulation. While the Pten-null livers developed profound
steatosis, the Tsc1-null livers had low TG stores. This phenotypic
difference correlated closely with their relative Akt and mTORC1
activities and suggested that the Tsc12/2 hepatocytes could be
protected from steatosis due to the feedback suppression of Akt by
mTORC1. In support of this, the Tsc12/2 livers were resistant to
high-fat diet-induced steatosis, and treatment with rapamycin
abolished this ‘protection’ resulting in hepatic TG accumulation
that was equivalent to that seen in the wild-type hepatocytes under
high-fat diet condition (Figure 8). Further, rapamycin led to the
inhibition of mTORC1 and S6K1 resulting in the de-repression of
Akt. Moreover, steatosis can be induced in the Tsc12/2
hepatocytes with the expression of Myr-Akt (Figure 7). These
observations highlight the strong association between the balance
of Akt and mTORC1 activities and the development of steatosis.
When Akt dominates over mTORC1 (e.g., Pten2/2), steatosis
ensues, whereaswhen mTORC1 overshadowsAkt(e.g.,Tsc12/2),
fat deposition is suppressed. Other models of Akt suppression in the
liver (i.e., deletion of hepatic insulin receptor or Akt2) also result in a
reduction in TG accumulation along with glucose intolerance
similar to that of the Tsc12/2 mice [44] [41]. Thus, inhibition of
hepatic Akt activity by any number of mechanisms leads to total
hepatic insulin resistance. On the contrary, increasing Akt function
in hepatocytes by direct (i.e., Pten ablation, expression of Myr-Akt,
high-fat diet) or indirect (i.e., de-repression by rapamycin) means
promotes lipogenesis and steatosis. These findings support our
conclusionthat the protective effect of mTORC1 from diet-induced
steatosis is mediated via the inhibition of Akt signaling and
underscore the potential for targeting Akt pharmacologically in
the treatment of steatosis.
Rapamycin is commonly used as an immunosuppressant
following renal transplant, and more recently, its analogs have
gained FDA approval for use in human tumors such as renal cell
carcinoma and subependymal giant cell astrocytoma. Reports of
rapamycin-induced glucose intolerance and dyslipidemia are
consistent with our observations. However, steatosis is not
consistently associated with the use of rapamycin in humans. We
reasoned that the degree of hepatic TG varies with the effects of
rapamycin on Akt activity. Sarbassov et al. reported that Akt
activity varies with the concentration and duration of rapamycin
treatment such that acute rapamycin alleviates S6K1 feedback
inhibition of Akt, but at higher concentrations and/or at longer
exposure, rapamycin can inhibit Akt by reducing mTORC2
complex formation [45]. Thus, the net result of chronic rapamycin
administration on Akt is difficult to predict. The rapamycin
regimens that were used in our experiments effectively suppressed
mTORC1 without significantly inhibiting Akt activity. Conse-
quently, the hepatic TG contents remained either unchanged
(Figure 4) or enhanced (Figure 8) correlating with the level of Akt
signaling and the balance between Akt and mTORC1. When used
for a protracted period (e.g., 2 mg/kg daily for 42 days), Chang et
al. reported that diet-induced steatosis was suppressed in wild-type
mice treated with rapamycin [34]. While Akt activity was not
reported in the study, we speculate that their regimen may have
inhibited Akt resulting in lowered TG accumulation. A more
detailed examination of this relationship and the balance between
Akt and mTORC1 activities in human NAFLD are potentially
informative.
Insulin promotes lipid synthesis through the induction of
SREBP1c and its target genes [46]. PI3K is the dominant
signaling node responsible for insulin action, and a number of
effectors downstream of PI3K have been implicated in hepatic
lipid synthesis including Akt, PKC-f and PKC-l [47]. While high-
fat diet leads to obesity and hyperinsulinemia, in the liver, HFD
induces a lipogenic response through the up-regulation of
SREBP1c and down-regulation of ATGL that is accompanied
by an increase in glucose kinase and a decrease in PEPCK
(Figure 9). These changes are consistent with augmented fat
synthesis and storage at the expense of utilizing glucose and
suppressing gluconeogenesis during the state of over-nutrition. To
the contrary, activation of mTORC1 leads to a metabolic switch
from glucose utilization towards fat utilization in the liver similar
to that seen during fasting or caloric restriction. Compared to wild-
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SREBP1c and GK expression while ATGL and PEPCK were
elevated, and these differences were recapitulated when fed a high-fat
diet. Importantly, rapamycin had opposing effects on the expression
o ft h e s em e t a b o l i ce n z y m e ss u g g e s t i n gt h a tm T O R C 1p l a y sac r i t i c a l
role on the regulation of hepatic lipid and glucose metabolism. Based
on the metabolic gene expression profile, the effects of rapamycin,
when given at a non-Akt suppressing dose, resembles that of HFD
feeding in promoting energy storage at the expense of burning
glucose(e.g.,markedly elevated glucose kinase and repressed PEPCK
expression, Figure 9). Correspondingly, the liver responds to
mTORC1 activation with a rapamycin-sensitive increase in PGC1a,
a key regulator of mitochondrial biogenesis, which is normally
induced under fasting conditions to facilitate glucose production.
Thus, the Tsc12/2 model highlights the novel function of hepatic
mTORC1 in enhancing gluconeogenesis while limiting the accumu-
lation of triglyceride by promoting lipid utilization.
Although mTORC1 has been implicated in de novo lipogenesis
in cells [10], the lack of TG accumulation in the Tsc1-null livers
when challenged with HFD suggests that mTORC1 is not the
primary ‘driver’ of steatosis in vivo. Instead, we surmise that
mTORC1 serves to ‘fine-tune’ Akt signaling in the regulation of
hepatic lipid metabolism. The mechanism of Akt-dependent
steatosis involves a number of down-stream effectors including
GSK3b and FoxO1. Akt phosphorylates GSK3b and FoxO1 to
inhibit their activities, and in the Tsc12/2 livers, these proteins
were hypo-phosphorylated (i.e., in the active state) (Figures 7, 9).
GSK3b limits lipogenesis by phosphorylating mature SREBP1
and promoting its proteasomal degradation through binding with
the Fbw7 ubiquitin ligase [48]. The effects of FoxO1 on hepatic
SREBP1 are less clear with reports showing mixed results [49]
[50] [51]. However, FoxO1 also regulates ATGL expression in
promoting triacylglycerol hydrolysis [37], and ATGL was found to
be significantly elevated in the Tsc12/2 livers (Figure 9). Loss-of-
function mutations of ATGL have been associated with TG
accumulation in patients with neutral lipid storage disease [52]. In
summary, our data suggest that mTORC1 suppresses lipid
accumulation through its feedback inhibition of Akt, which, in
turn, modulates lipogenic and lipolytic activities through its
effectors, GSK3b and FoxO1. These results also highlight the in
vivo relevance of the mTORC1-Akt feedback mechanism in
regulating hepatic lipid metabolism and energy balance.
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